Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone

References

• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. doi:10.1002/ajh.25792
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015;125(21):3230–3235. doi:10.1182/blood-2014-10-567784
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the chronic leukemia working party of the european group for blood and marrow transplantation (EBMT). Haematologica. 2006;91(4):513–521.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after bcr-abl kinase mutation–related imatinib failure. Blood. 2006;108(4):1421–1423. doi:10.1182/blood-2006-02-001933
   PubMed Web of Science ®Google Scholar
• Craddock CF. We do still transplant CML, don’t we? Hematology Am Soc Hematol Educ Program. 2018;2018(1):177–184. doi:10.1182/asheducation-2018.1.177
   PubMedGoogle Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–1987. doi:10.1182/blood-2011-08-358135
   PubMed Web of Science ®Google Scholar
• Goldman J, McCarthy D, Hows J, et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet. 1982;2(8299):623–625. doi:10.1016/s0140-6736(82)92736-2
   PubMed Web of Science ®Google Scholar
• Mcglave P, Kim T, Hurd D, et al. Successful allogeneic bone-marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia. Lancet. 1982;2(8299):625–627. doi:10.1016/s0140-6736(82)92737-4
   PubMed Web of Science ®Google Scholar
• Clift R, Thomas E, Fefer A, et al. Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet. 1982;2(8299):621–623. doi:10.1016/s0140-6736(82)92735-0
   PubMed Web of Science ®Google Scholar
• Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108(6):806–814. doi:10.7326/0003-4819-108-6-806
   PubMed Web of Science ®Google Scholar
• Pavlu J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117(3):755–763. doi:10.1182/blood-2010-08-301341
   PubMed Web of Science ®Google Scholar
• Goldman JM. Allogeneic stem cell transplantation for chronic myeloid leukemia–status in 2007. Bone Marrow Transplant. 2008;42 Suppl 1(S1):S11–S13. doi:10.1038/bmt.2008.105
   PubMedGoogle Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after. Bone Marrow Transplant. 1990;6 Suppl 1:94–97.
   PubMed Web of Science ®Google Scholar
• Kolb H, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia [see comments]. Blood. 1995;86(5):2041–2050. doi:10.1182/blood.V86.5.2041.bloodjournal8652041
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400. doi:10.1182/blood.v97.11.3390
   PubMed Web of Science ®Google Scholar
• Chhabra S, Ahn KW, Hu ZH, et al. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018;2(21):2922–2936. doi:10.1182/bloodadvances.2018024844
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143–5150. doi:10.1182/blood-2006-11-056028
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141–1145. doi:10.1182/blood-2010-03-277152
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123(9):1309–1318. doi:10.1182/blood-2013-07-513937
   PubMed Web of Science ®Google Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–2326. doi:10.1056/NEJMoa1902328
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Basak GW, Kim DW, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123(15):2875–2880. doi:10.1002/cncr.30558
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404. doi:10.1182/blood-2016-09-739086
   PubMed Web of Science ®Google Scholar
• Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma. 2005;46(5):781–784. doi:10.1080/10428190500046778
   PubMed Web of Science ®Google Scholar
• Song M-K, Choi Y-J, Seol Y-M, et al. Nilotinib-induced bone marrow aplasia. Eur J Haematol. 2009;83(2):161–162. doi:10.1111/j.1600-0609.2009.01269.x
   PubMed Web of Science ®Google Scholar
• Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized german CML study IV. Blood. 2010;115(10):1880–1885. doi:10.1182/blood-2009-08-237115
   PubMed Web of Science ®Google Scholar
• Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood. 2005;106(9):2969–2976. doi:10.1182/blood-2004-09-3544
   PubMed Web of Science ®Google Scholar
• Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012;119(17):4083–4090. doi:10.1182/blood-2012-02-409763
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93(12):1792–1796. doi:10.3324/haematol.13068
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Masszi T, Shen Z, et al. Expanding nilotinib access in clinical trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012;53(5):907–914. doi:10.3109/10428194.2011.627480
   PubMed Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852–3861. doi:10.1002/cncr.25123
   PubMed Web of Science ®Google Scholar
• Giles F, Kantarjian H, Le Coutre P, et al. Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012;26(5):959–962. doi:10.1038/leu.2011.355
   PubMed Web of Science ®Google Scholar
• Jiang Q, Xu L-P, Liu D-H, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117(11):3032–3040. doi:10.1182/blood-2010-09-308510
   PubMed Web of Science ®Google Scholar
• Silver RT, Cortes J, Waltzman R, et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94(5):743–744. doi:10.3324/haematol.2009.006999
   PubMed Web of Science ®Google Scholar
• Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. 2020.
   Google Scholar
• Hehlmann R, Saußele S, Voskanyan A, et al. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016;29(3):295–307. doi:10.1016/j.beha.2016.10.005
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Ibrahim A, Reid A, et al. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica. 2012;97(3):473–474. doi:10.3324/haematol.2011.057513
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017;123(22):4391–4402. doi:10.1002/cncr.30864
   PubMed Web of Science ®Google Scholar
• Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006;20(3):400–403. doi:10.1038/sj.leu.2404115
   PubMed Web of Science ®Google Scholar
• Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014;120(3):373–380. doi:10.1002/cncr.28433
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650–3656. doi:10.1002/cncr.30231
   PubMed Web of Science ®Google Scholar
• Jiang H, Xu LP, Liu DH, et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant. 2014;49(9):1146–1154. doi:10.1038/bmt.2014.146
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Breccia M, Saglio G, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34(6):1495–1502. doi:10.1038/s41375-020-0842-9
   PubMed Web of Science ®Google Scholar
• Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014;14(2):155–162.e1. doi:10.1016/j.clml.2013.08.008
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi:10.1182/blood-2005-05-2004
   PubMed Web of Science ®Google Scholar
• Shimazu Y, Murata M, Kondo T, et al. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. Hematol Oncol. 2022;40(3):442–456. doi:10.1002/hon.3000
   PubMed Web of Science ®Google Scholar
• Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109(4):1782–1789. doi:10.1182/blood-2006-06-031682
   PubMed Web of Science ®Google Scholar
• Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91(4):452–459.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112(8):3500–3507. doi:10.1182/blood-2008-02-141689
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012;47(6):810–816. doi:10.1038/bmt.2011.194
   PubMed Web of Science ®Google Scholar
• Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2010;34(2):143–147. doi:10.1016/j.leukres.2009.04.036
   PubMed Web of Science ®Google Scholar
• Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: striking the right balance. Nat Rev Clin Oncol. 2016;13(2):79–91. doi:10.1038/nrclinonc.2015.193
   PubMed Web of Science ®Google Scholar
• Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101(2):441–445. doi:10.1182/blood-2002-02-0535
   PubMed Web of Science ®Google Scholar
• Kerbauy FR, Storb R, Hegenbart U, et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia. 2005;19(6):990–997. doi:10.1038/sj.leu.2403730
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007;110(9):3456–3462. doi:10.1182/blood-2007-04-085969
   PubMed Web of Science ®Google Scholar
• Das M, Saikia TK, Advani SH, et al. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant. 2003;32(2):125–129. doi:10.1038/sj.bmt.1704107
   PubMed Web of Science ®Google Scholar
• Negrin RS. Graft-versus-host disease versus graft-versus-leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):225–230. doi:10.1182/asheducation-2015.1.225
   PubMedGoogle Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, Double-Blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-Host disease-free survival in patients undergoing HLA-Matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003–4011. doi:10.1200/JCO.2017.75.8177
   PubMed Web of Science ®Google Scholar
• Poiré X, Artz A, Larson RA, et al. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009;50(1):85–91. doi:10.1080/10428190802626624
   PubMed Web of Science ®Google Scholar
• Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95(1):67–71. doi:10.1182/blood.V95.1.67
   PubMed Web of Science ®Google Scholar
• Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003;17(9):1707–1712. doi:10.1038/sj.leu.2403068
   PubMedGoogle Scholar
• Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006;91(5):663–666.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Tsai H-L, Bolaños-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124(25):3817–3827. doi:10.1182/blood-2014-07-587477
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Solomon SR, Solh M, Morris LE, et al. Myeloablative conditioning with PBSC grafts for T cell-Replete haploidentical donor transplantation using posttransplant cyclophosphamide. Adv Hematol. 2016;2016:9736564–9736567. doi:10.1155/2016/9736564
   PubMedGoogle Scholar
• Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006;107(10):4171–4176. doi:10.1182/blood-2005-08-3320
   PubMed Web of Science ®Google Scholar
• Arpinati M, Tolomelli G, Bochicchio MT, et al. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2013;19(5):735–740. doi:10.1016/j.bbmt.2013.01.007
   PubMed Web of Science ®Google Scholar
• Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28(11):1888–1895. doi:10.1200/JCO.2009.26.7757
   PubMed Web of Science ®Google Scholar
• Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96(8):2712–2716. doi:10.1182/blood.V96.8.2712
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Passweg JR, Schmid C, et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplant. 2010;45(3):558–564. doi:10.1038/bmt.2009.177
   PubMed Web of Science ®Google Scholar
• Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(11):1009–1015. doi:10.1038/sj.bmt.1705167
   PubMed Web of Science ®Google Scholar
• Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007;110(13):4614–4617. doi:10.1182/blood-2007-04-082990
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk philadelphia chromosome-positive leukemia. Blood. 2007;109(7):2791–2793. doi:10.1182/blood-2006-04-019836
   PubMed Web of Science ®Google Scholar
• Nakasone H, Kanda Y, Takasaki H, et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with philadelphia chromosome-positive leukemia. Leukemia. 2010;24(6):1236–1239. doi:10.1038/leu.2010.83
   PubMed Web of Science ®Google Scholar
• DeFilipp Z, Ancheta R, Liu Y, et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2020;26(3):472–479. doi:10.1016/j.bbmt.2019.10.017
   PubMedGoogle Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392–399. doi:10.3324/haematol.2014.116954
   PubMed Web of Science ®Google Scholar
• Saini N, Marin D, Ledesma C, et al. Impact of TKIs post–allogeneic hematopoietic cell transplantation in philadelphia chromosome–positive ALL. Blood. 2020;136(15):1786–1789. doi:10.1182/blood.2019004685
   PubMed Web of Science ®Google Scholar
• Warraich Z, Tenneti P, Thai T, et al. Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for philadelphia chromosome–positive acute lymphoblast leukemia: a systematic review. Biol Blood Marrow Transplant. 2020;26(3):e55–e64. doi:10.1016/j.bbmt.2019.09.022
   PubMedGoogle Scholar
• Lipton JH. The expanding CML treatment landscape: an introspective commentary. Blood Cancer J. 2023;13(1):145. doi:10.1038/s41408-023-00918-3
   PubMed Web of Science ®Google Scholar
• Godara A, Siddiqui NS, Munigala S, et al. Length of stay and hospital costs for patients undergoing allogeneic stem-cell transplantation. J Clin Oncol Oncol Pract. 2021;17(3):e355–e68. doi:10.1200/OP.20.00170
   PubMedGoogle Scholar
• Ruiz-Argüelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant. 2008;42(1):23–28. doi:10.1038/bmt.2008.90
   PubMed Web of Science ®Google Scholar